NICE confirms Pradaxa recommendation
This article was originally published in Scrip
Guidance published for the national health service in England and Wales confirms theNational Institute for health and Clinical Excellence's recommendation thatBoehringer Ingelheim's Pradaxa (dabigatran etexilate) be an option for the primary prevention of venous thromboembolic events in adults who have undergone elective total hip replacement surgery or elective total knee replacement surgery. The direct thrombin inhibitor was licensed by the EU in March and given a tentative NICE recommendation in July (Scrip Online, August 1st, 2008). The appraisal committee concluded that Pradaxa was as cost-effective as low-molecular weight heparin or fondaparinux, taking into account the benefits of its oral formulation. Boehringer Ingelheim says it is the first new oral anticoagulant to be launched in the UK for over 50 years.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.